{{Rsnum
|rsid=1734792
|Gene=MECP2
|Chromosome=X
|position=154075609
|Orientation=plus
|GMAF=0.3718
|Gene_s=MeCP2,MECP2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 15.9 | 9.7 | 74.3
| HCB | 68.6 | 25.5 | 5.8
| JPT | 65.5 | 15.9 | 18.6
| YRI | 16.3 | 18.4 | 65.3
| ASW | 3.5 | 24.6 | 71.9
| CHB | 68.6 | 25.5 | 5.8
| CHD | 73.4 | 15.6 | 11.0
| GIH | 44.6 | 18.8 | 36.6
| LWK | 10.9 | 20.0 | 69.1
| MEX | 22.4 | 29.3 | 48.3
| MKK | 24.4 | 23.1 | 52.6
| TSI | 8.8 | 21.6 | 69.6
| HapMapRevision=28
}}[[rs1734792]] is one of several SNPs in the methyl CpG binding protein 2 ([[MECP2]]) that have been associated with risk for systemic [[lupus]] erythromatosis (SLE). The [[MECP2]] gene is located on the X chromosome, which may be instructive since lupus is a predominantly female disease.

An initial survey of 600 Korean patients, followed by 1,000 Caucasian patients, ultimately led to a meta-analysis indicating an odds ratio for the [[rs1734792]](A) risk allele of 1.42 (CI: 1.24-1.58, p = 3.3E-08).{{PMID|18320046|OA=1
}}

{{PMID|19333917|OA=1
}} Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus.

{{PMID Auto
|PMID=23233309
|Title=An activity-enhancing variant of IRAK1 and an MECP2-IRAK1 haplotype associating with increased susceptibility to rheumatoid arthritis
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}